Guizhou Yibai Pharmaceutical Co Ltd Asset Resilience Ratio

Latest as of June 2025: 0.49%

Guizhou Yibai Pharmaceutical Co Ltd asset resilience ratio. Guizhou Yibai Pharmaceutical Co Ltd (600594) has an Asset Resilience Ratio of 0.49% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Guizhou Yibai Pharmaceutical Co Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥20.00 Million

≈ $2.93 Million USD Cash + Short-term Investments

Total Assets

CN¥4.05 Billion

≈ $592.98 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Guizhou Yibai Pharmaceutical Co Ltd (2024–2024)

Asset resilience ratio of Guizhou Yibai Pharmaceutical Co Ltd from 2024 to 2024. This chart shows how Guizhou Yibai Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See 600594 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down Guizhou Yibai Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Guizhou Yibai Pharmaceutical Co Ltd.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥20.00 Million	0.49%
Total Liquid Assets	CN¥20.00 Million	0.49%

Asset Resilience Insights

Limited Liquidity: Guizhou Yibai Pharmaceutical Co Ltd maintains only 0.49% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Guizhou Yibai Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Guizhou Yibai Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Galderma Group N SW:GALD	Drug Manufacturers - Specialty & Generic	3.56%
Enzymatica publ AB ST:ENZY	Drug Manufacturers - Specialty & Generic	22.17%
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	Drug Manufacturers - Specialty & Generic	9.04%
Hubei Jumpcan Pharmaceutical Co Ltd SHG:600566	Drug Manufacturers - Specialty & Generic	47.16%
Kangmei Pharmaceutical Co Ltd SHG:600518	Drug Manufacturers - Specialty & Generic	0.00%
Walvax BioTech SHE:300142	Drug Manufacturers - Specialty & Generic	2.20%
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	Drug Manufacturers - Specialty & Generic	3.47%

Guizhou Yibai Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2024–2024)

Guizhou Yibai Pharmaceutical Co Ltd asset resilience ratio by year from 2024 to 2024. The table below shows the annual Asset Resilience Ratio data for Guizhou Yibai Pharmaceutical Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.49%	CN¥20.00 Million ≈ $2.93 Million	CN¥4.10 Billion ≈ $599.92 Million	--

pp = percentage points

About Guizhou Yibai Pharmaceutical Co Ltd

SHG:600594 China Drug Manufacturers - Specialty & Generic

Market Cap

$369.67 Million

CN¥2.53 Billion CNY

Market Cap Rank

#13480 Global

#3928 in China

Share Price

CN¥3.19

Change (1 day)

+0.00%

52-Week Range

CN¥2.95 - CN¥5.06

All Time High

CN¥19.64